Activity Number:
|
88
- Biopharmaceutical Section A.M. Roundtable Discussion (Added Fee)
|
|
Type:
|
Roundtables
|
|
Date/Time:
|
Monday, July 30, 2018 : 7:00 AM to 8:15 AM
|
|
Sponsor:
|
Biopharmaceutical Section
|
|
Abstract #330916
|
|
|
Title:
|
Composite Endpoints for Alzheimer's Disease Clinical Trials
|
|
Author(s):
|
Steve Edland*
|
|
Companies:
|
University of California, San Diego
|
|
Keywords:
|
clinical trials;
statistical power;
quantitative trait endpoints;
MRI;
Alzheimer's disease
|
|
Abstract:
|
Composite endpoints have received increasing attention as potential outcome measures for clinical trials in Alzheimer's disease. We have recently derived the weighted sum of component scales that maximize signal-to-noise of resulting composite scales (Ard et al. Optimal composite scores for longitudinal clinical trials under the linear mixed effects model. Pharm Stat. 2015;14(5):418 26) and maximizes their power as endpoints for clinical trials. This Discussion session with review concepts of composite scales using recent published examples of applications to volumetric MRI endpoints [Edland, et al. (2017) Alzheimer's & Dementia: Translational Research & Clinical Intervention. 2(3):177-181] and cognitive function endpoints [Edland et al. (2016) Alzheimer's & Dementia, doi: 10.1016/j.trci.2016.12.004] for clinical trials in Alzheimer's disease.
|
Authors who are presenting talks have a * after their name.
